SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and full year 2015 and provided a corporate update on its clinical development plans for 2016.
“We had a productive fourth quarter as we completed enrollment in our Phase 2b fispemifene trial and remain on schedule to report fispemifene Phase 2b top-line data by the end of the first quarter of 2016,” stated Richard Pascoe, Chief Executive Officer. “Additionally, we continued to experience record Vitaros sales in Europe and according to data obtained from IMS Midas, Vitaros retail unit sales in Europe continued to demonstrate robust double-digit growth from approximately 268,500 units in the third quarter of 2015 to approximately 330,600 units in the fourth quarter of 2015. Apricus also remains on track in the second half of 2016 to resubmit the New Drug Application (“NDA”) for Vitaros U.S. and to continue its clinical development of RayVa.”
“We had a productive fourth quarter as we completed enrollment in our Phase 2b fispemifene trial and remain on schedule to report fispemifene Phase 2b top-line data by the end of the first quarter of 2016,” stated Richard Pascoe, Chief Executive Officer. “Additionally, we continued to experience record Vitaros sales in Europe and according to data obtained from IMS Midas, Vitaros retail unit sales in Europe continued to demonstrate robust double-digit growth from approximately 268,500 units in the third quarter of 2015 to approximately 330,600 units in the fourth quarter of 2015. Apricus also remains on track in the second half of 2016 to resubmit the New Drug Application (“NDA”) for Vitaros U.S. and to continue its clinical development of RayVa.”
